Fc portion of monoclonal antibody (Fc region)

The **Fc portion of a monoclonal antibody**, also called the fragment crystallizable region, is the constant tail region of an antibody molecule that interacts with specialized cell surface receptors (Fc receptors) and components of the complement system[1][3][4][5]. This region does not bind antigen, but is essential for initiating immune effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC)[5][7]. Different antibody classes (e.g., IgG, IgA, IgM) have distinctly structured Fc regions which determine their effector profiles. In therapeutic monoclonal antibodies, engineering the Fc region can modulate immune engagement, extend antibody half-life by altering interaction with the neonatal Fc receptor (FcRn), or reduce effector functions to limit toxicity[5][6]. The Fc portion itself is **not a traditional drug target** (e.g., it is not a receptor, enzyme, or transporter targeted by small molecules or biologics), but rather a structural component that can be optimized to affect how therapeutic antibodies function in the body[1][3][5]. **Key note:** The "Fc portion of therapeutic monoclonal antibodies" is not considered a canonical therapeutic target. Instead, it is a critical structural element of the antibodies themselves, which are the actual therapeutics. The information above is intended to clarify the role, molecular nature, and significance of the Fc region in therapy.

Other names

Fc fragmentfragment crystallizable regionconstant region (incorrect usage)Fc domain

Not applicable as a direct target; Fc engineering in antibody drugs can: - Enhance or reduce effector functions by modifying interactions with Fc receptors or complement - Extend antibody half-life by improving binding to FcRn - Alter immune cell recruitment and cytotoxic mechanisms[5][6]